James DArecca - 10 Aug 2021 Form 4 Insider Report for TherapeuticsMD, Inc. (TXMD)

Role
Chief Financial Officer
Signature
/s/ James C. D'Arecca
Issuer symbol
TXMD
Transactions as of
10 Aug 2021
Net transactions value
-$81,203
Form type
4
Filing time
12 Aug 2021, 21:33:45 UTC
Previous filing
02 Jul 2021
Next filing
14 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXMD Common Stock Options Exercise +217,167 217,167 10 Aug 2021 Direct F1
transaction TXMD Common Stock Sale $81,203 -93,337 -43% $0.8700* 123,830 12 Aug 2021 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXMD Restricted Stock Units Options Exercise $0 -217,167 -33% $0.000000 434,333 10 Aug 2021 Common Stock 217,167 $0.000000 Direct F1, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On August 10, 2021, the reporting person received 217,167 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021.
F2 The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
F3 This transaction was executed in multiple trades at prices ranging from $0.87 to $0.88. The price reported in Column 4 reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F4 Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.
F5 The RSUs vest in three equal installments annually beginning June 1, 2021 (the one-year anniversary of the date of the reporting person's appointment as Chief Financial Officer), becoming fully vested on June 1, 2023.